Antibodies and Microarrays

Antibodies are important tools in many research and diagnostic applications.
Zedira offers antibodies – polyclonal as well as monoclonal – raised against:

  • All human transglutaminases
  • Guinea pig liver transglutaminase
  • Bacterial transglutaminase
  • The transglutaminase reaction product: Nε-(γ-glutamyl)-L-lysine-isopeptide bond
  • Fibrinolytic enzymes: Plasmin and its zymogen (plasminogen)
  • Gliadin-variants

Antibody epitope mapping
PEPperPRINT and Zedira commonly present the new PEPperCHIP® Transglutaminase Microarray!
Standard and Custom PEPperCHIP® Peptide Microarrays are synthesized with a unique laser printer based method directly on-chip and are used for e.g. antibody epitope mapping, immunological research, and biomarker discovery.

Read more about PEPperCHIP® Laser Printing Platform

Antibodies labeled with fluorescent dyes
Zedira provides many of it‘s polyclonal antibodies with a flourescent label like FITC or phycoerythrin or as a biotinylated version. Of course antibodies with other tags are available on demand.

Indirect immuno-staining with A014
Indirect immuno-staining with A014
Indirect immuno-staining with A017

Indirect immuno-stainings
(A) Anti TG2 (A014): mouse colon section (1:100);
(B) Anti TG2 (A014): mouse small intestinal mucosa;
(C) Anti-TG6 (A017): astrocyte in mouse corpus callosum.

(A/B) J. Knauer, Fraunhofer Gesellschaft Leipzig; (C) A. Schulze-Krebs, S. v. Hörsten, University Erlangen

In many applications the need for a fluorescently labeled antibody exists, ranging from fluorescence microscopy to fluorescence-activated cell sorting (FACS).

Transmitted light microscopy
FITC-Anti-TG2 with A028
FITC-Anti-TG2 with A027
Direct Immuno-Stainings
(A) Transmitted light microscopy, magnification 1:40;
(B) FITC-Anti-TG2 (A028): fluorescence microscopy, magnification 1:40;
(C) FITC-Anti-TG2 (A028): fluorescence microscopy, magnification 1:20.

(A-C) W. Dieterich, University Erlangen-Nürnberg


  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.


  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
  • Zedira supports Gordon Research Conference
  • imagePress release: Zedira announces ISO 9001:2015 certification
  • imageZedira communication: Joint poster presentation on “Feasibility of a new automated FXIII activity assay”
  • imageArtikel in DZG Aktuell 01/2019 über die klinische Wirksamkeitsstudie unseres potentiellen Zöliakie Medikaments (deutsch)
  • imagePreview: Catalogue Editorial 2019
  • Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
  • Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation



  • 19th International Celiac Disease Symposium

    14.10.2021 - 17.10.2021
    Sorrento, Italy

  • Gordon Research Conference: Transglutaminases in Human Disease Processes

    12.06.2022 - 17.06.2022
    Mount Snow, USA